Allworth Financial LP Lowers Position in Edwards Lifesciences Corporation $EW

Key Points

• Allworth Financial reduced its Edwards Lifesciences position by 58.5% in the second quarter, selling 23,421 shares and retaining 16,600 shares valued at approximately $1.5 million. Institutional investors still own about 79.5% of the company.
• Analysts remain broadly positive, with 17 Buy ratings and six Holds, producing a “Moderate Buy” consensus and an average price target of $100.27. Recent coverage included UBS initiating a Buy rating with a $110 target and RBC raising its target to $110.
• Edwards reported quarterly EPS of $0.78, beating estimates of $0.74, while revenue rose 13.6% year over year to $1.74 billion. The stock recently traded at $84.54, down 2.6%, while expanded Medicare coverage for certain TAVR patients could support future demand.

Allworth Financial LP decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 58.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,600 shares of the medical research company's stock after selling 23,421 shares during the period. Allworth Financial LP's holdings in Edwards Lifesciences were worth $1,502,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Rehmann Capital Advisory Group grew its holdings in Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock valued at $546,000 after buying an additional 130 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in shares of Edwards Lifesciences by 0.9% in the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company's stock valued at $1,288,000 after purchasing an additional 136 shares in the last quarter. Stephens Inc. AR grew its holdings in shares of Edwards Lifesciences by 5.4% during the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company's stock worth $239,000 after purchasing an additional 144 shares during the period. Aspen Investment Management Inc increased its position in Edwards Lifesciences by 1.5% during the 4th quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company's stock worth $885,000 after purchasing an additional 150 shares in the last quarter. Finally, Covestor Ltd increased its position in Edwards Lifesciences by 9.6% during the 4th quarter. Covestor Ltd now owns 1,784 shares of the medical research company's stock worth $152,000 after purchasing an additional 157 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. UBS Group began coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a "buy" rating and a $110.00 price target for the company. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a report on Monday, July 13th. JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Finally, TD Cowen reissued a "buy" rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

Insiders Place Their Bets

In other news, VP Annette Brüls sold 2,644 shares of the business's stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president directly owned 17,984 shares of the company's stock, valued at $1,618,200.32. The trade was a 12.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. The trade was a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,664 shares of company stock worth $511,918 in the last ninety days. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Trading Down 2.6%

Shares of NYSE EW opened at $84.54 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock has a market cap of $48.68 billion, a price-to-earnings ratio of 48.59, a PEG ratio of 2.28 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The business has a 50 day simple moving average of $89.16 and a 200 day simple moving average of $85.79.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the firm posted $0.67 EPS. The firm's revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.